{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-026621","form_type":"8-K","ticker":"CYCN","cik":"0001755237","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2023-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.397071+00:00","generated_at":"2026-06-14T14:45:09.797300+00:00","sec_items":["3.02","5.03","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CEO Peter Hecht invests $5M in Cyclerion; receives 225K common shares and 351K Series A convertible preferred","bullets":["Peter Hecht, CEO, purchased $5M in equity at $8.68 per share (post-1-for-20 reverse split).","Issued 225,000 shares of common stock and 351,037 shares of Series A convertible preferred (1:1 conversion).","Hecht agreed not to convert preferred if it would require Nasdaq shareholder approval.","Transaction completed May 19, 2023; exempt from registration under Regulation D and Section 4(a)(2).","Filed Articles of Amendment to designate Series A Preferred Stock; no shareholder approval needed for issuance."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-026621","json":"https://secwatch.observer/filing/0001140361-23-026621.json","markdown":"https://secwatch.observer/filing/0001140361-23-026621.md","text":"https://secwatch.observer/filing/0001140361-23-026621.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1755237/000114036123026621/0001140361-23-026621-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1755237/000114036123026621/brhc20053546_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T14:45:09.797300+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e51008f6dbeebdc2b02d79ca3919ad0e2cef3856","claim":"Cyclerion Therapeutics, Inc.: Filed Articles of Amendment to designate Series A Preferred Stock (effective 2023-05-19).","evidence_excerpt":"On May 19, 2023 , the Company filed with the Secretary of the Commonwealth of the Commonwealth of Massachusetts Articles of Amendment (the “Articles of Amendment”) to the Company’s Restated Articles of Organization, as amended, designating shares of the Series A Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1755237/000114036123026621/0001140361-23-026621-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-05-19"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}